November 21, 2022
Kyowa Kirin’s and MEI Pharma’s oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor zandelisib has met the primary endpoint in a Japanese PII study for the treatment of indolent B-cell non-Hodgkin’s lymphoma, according to their topline data. The PII MIRAGE study looked...read more